Filament Health Corp. (7QS.F)

Compare

0.0175

0.0000

(0.00%)

At close: January 28 at 8:11:33 AM GMT+1

FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has shipped its botanical psilocybin drug candidate, PEX010, to the University of Wisconsin–Madison (UW–Madison) for investigation in two clinical trials. Both trials are United States Food and Drug Administration (FDA)-authorized and will study the effects of psilocybin on neuroplasticity.

CNW Group 7 days ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences ("Magdalena"), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) ("Jaguar Health"), successfully completed an import of six kilograms of coca leaf from Peru to Filament's Metro Vancouver research and development facility. This is the second import of coca leaf that Magdale

CNW Group last month

FLHLF
0.00%
JAGX
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2024.

CNW Group 2 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that, it has issued 5,600,000 common shares in the capital of the Company (the "Common Shares") at a price of $0.05 per Common Share to Filament Health SPV – Allocations Funds LLC, Bioconnect Ventures – Allocations Funds LLC, and Sovereign74, LLC. The Common Shares are being issued to pursuant to an advisory agreement (the "Ad

CNW Group 3 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024.

CNW Group 5 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has expanded its intellectual property (IP) portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs. Filament has been issued a further five patents by the Canadian Intellectual Property Office (CIPO), and three patents by the United State

CNW Group 5 months ago

FLHLF
0.00%
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the "Common Shares") from the conversion of a convertible note due July 13, 2024 ("Note") and the exercise of the Acquiror's outstanding warrants ("Warrants") to purchase Common Shares (collectively, the "Transaction"). In connection with the Transact

Newsfile 7 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that, further to its press release dated June 3, 2024, it has completed its previously announced C$1.0 million bridge financing (the "Financing").

CNW Group 7 months ago

FLHLF
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6-10-24

Key Takeaways; Cannabis Sector Canopy Growth to fully acquire Acreage Holdings in strategic move AFC Gamma exited its largest portfolio loan, securing 19.9% return. Green Thumb CEO confirmed proposal to Boston Beer. Scotts Miracle-Gro adjusted financial outlook for 2024 but maintained strategic goals. Key Takeaways; Psychedelic Sector Filament Health received FDA approval for a meth […]

Market Exclusive 7 months ago

CGC

FLHLF
0.00%
AFCG
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced Health Canada and the United States Food and Drug Administration ("FDA") authorization for a Phase 2 clinical trial of PEX010, Filament's botanical psilocybin drug candidate, for the treatment of methamphetamine use disorder ("MAUD"). This will be the first ever clinical trial to study the safety and efficacy of botanical psilo

CNW Group 7 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has entered into agreements with Negev Capital Fund One, LP ("Negev"), a leading psychedelic drug development venture fund and existing investor in the Company, and Benjamin Lightburn, the Chief Executive Officer and Co-Founder of the Company, to complete a C$1.0 million bridge financing (the "Financing").

CNW Group 7 months ago

FLHLF
0.00%
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments ...

ACCESS Newswire 7 months ago

FLHLF
0.00%
JAGX
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024.

CNW Group 8 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024.

CNW Group 8 months ago

FLHLF
0.00%
FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET.

CNW Group 9 months ago

FLHLF
0.00%
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2023.

CNW Group 9 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the "Board"). Mr. Messinger will also serve as the Chair of the Company's Audit Committee.

CNW Group 9 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for a range of mental health indications such as cannabis use disorder, depression, anxiety, and alcoho

CNW Group 10 months ago

FLHLF
0.00%
FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Israel. The shipment is believed to be the first botanical psilocybin to be exported to Israel. Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resist

CNW Group 11 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES FDA OPENING OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SUBSTANCE USE DISORDERS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PEX010, its botanical psilocybin drug candidate, for the treatment of Substance use Disorders (SUD).

CNW Group 11 months ago

FLHLF
0.00%

Performance Overview

Return	7QS.F	MSCI WORLD
YTD	+29.63%	+3.21%
1-Year	-66.67%	0.00%
3-Year	-84.51%	+27.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Filament Health Corp. (7QS.F)

FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6-10-24

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS

FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION

FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL

FILAMENT HEALTH ANNOUNCES FDA OPENING OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SUBSTANCE USE DISORDERS

Performance Overview